Published in PLoS One on April 30, 2013
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV (2015) 2.17
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial. Clin Infect Dis (2016) 1.44
HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neurovirol (2014) 1.10
Controversies in HIV-associated neurocognitive disorders. Lancet Neurol (2014) 1.07
Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob Agents Chemother (2013) 0.91
A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS (2015) 0.90
Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.87
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. PLoS One (2014) 0.86
HIV-1 transgenic female rat: synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J Neuroimmune Pharmacol (2014) 0.84
Identifying Neurocognitive Decline at 36 Months among HIV-Positive Participants in the CHARTER Cohort Using Group-Based Trajectory Analysis. PLoS One (2016) 0.80
Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors. Clin Infect Dis (2016) 0.75
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. J Antimicrob Chemother (2016) 0.75
A Gap in Time: Extending our Knowledge of Temporal Processing Deficits in the HIV-1 Transgenic Rat. J Neuroimmune Pharmacol (2016) 0.75
Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis (2016) 0.75
Primary care of women aging with HIV. J Midwifery Womens Health (2015) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology (2004) 2.54
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol (2004) 2.22
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS (2004) 1.84
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology (2011) 1.65
Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol (2011) 1.51
Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav (2011) 1.33
Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis (2011) 1.30
Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature. J Int Neuropsychol Soc (2011) 1.25
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med (2010) 1.23
Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol (2011) 1.20
Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials (2011) 1.11
Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res (2005) 1.05
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med (2011) 0.97
Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults. J Clin Exp Neuropsychol (2011) 0.88
Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study. J Pharmacol Exp Ther (2006) 0.87
Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect (2010) 0.84
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS (2002) 5.67
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect (2009) 3.92
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis (2003) 3.10
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis (2003) 2.12
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog (2009) 2.10
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Use of mycobacterial interspersed repetitive unit-variable-number tandem repeat typing to examine genetic diversity of Mycobacterium tuberculosis in Singapore. J Clin Microbiol (2004) 2.05
Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr (2007) 2.02
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis (2009) 1.96
Ten years of bacterial genome sequencing: comparative-genomics-based discoveries. Funct Integr Genomics (2006) 1.86
Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS (2004) 1.84
High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis (2009) 1.78
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry (2005) 1.74
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.70
Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol (2009) 1.70
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 1.62
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr (2004) 1.61
ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem (2004) 1.60
Seroepidemiology of dengue in the adult population of Singapore. Trop Med Int Health (2004) 1.59
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Acute hepatitis C: changing epidemiology and association with HIV infection. J HIV Ther (2007) 1.55
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet (2002) 1.54
Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of sexually transmitted infections and HIV among female sex workers. Sex Transm Infect (2009) 1.53
Sexually transmitted infections in female sex workers in five border provinces of Vietnam. Sex Transm Dis (2005) 1.53
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis (2005) 1.46
Human immunodeficiency virus (HIV) infection patterns and risk behaviours in different population groups and provinces in Viet Nam. Bull World Health Organ (2007) 1.43
The human immunodeficiency virus and ageing. Age Ageing (2014) 1.42
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Late diagnosis of HIV infection: major consequences and missed opportunities. Curr Opin Infect Dis (2008) 1.40
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
An outbreak of primary dengue infection among migrant Chinese workers in Singapore characterized by prominent gastrointestinal symptoms and a high proportion of symptomatic cases. J Clin Virol (2005) 1.39
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis (2007) 1.39
Limitations of proposed novel trial design. AIDS (2012) 1.39
Medical training in school-based health centers: a collaboration among five medical schools. Acad Med (2007) 1.37
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Use of simple laboratory features to distinguish the early stage of severe acute respiratory syndrome from dengue fever. Clin Infect Dis (2004) 1.35
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J (2006) 1.33
Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Int J Dermatol (2007) 1.32
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst (2010) 1.31
Suicidal ideation in UK HIV clinic attenders. AIDS (2008) 1.31
HIV-related risk behaviors in Cambodia and effects of mobility. J Acquir Immune Defic Syndr (2006) 1.28
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS (2007) 1.28
Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis (2008) 1.26
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Tuberculosis associated with Mycobacterium tuberculosis Beijing and non-Beijing genotypes: a clinical and immunological comparison. BMC Infect Dis (2006) 1.25
Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS (2009) 1.23
Why some MSM present late for HIV testing: a qualitative analysis. AIDS Care (2011) 1.23
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis (2008) 1.21
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. J Child Adolesc Psychopharmacol (2013) 1.19
Analysis of protein solvent interactions in glucose dehydrogenase from the extreme halophile Haloferax mediterranei. Proc Natl Acad Sci U S A (2006) 1.19
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med (2011) 1.17